The company's share fell directly in the initial trading on Tuesday morning below the issue price of SEK 5 and is currently trading at just over SEK 4. The warrants (TO1) that entitle to subscribe for shares at a price of SEK 5 at the beginning of 2017 are currently trading at around SEK 1, which corresponds to a share price of SEK 6.
BioStock has made an analysis and valuation of Xintela which can be read here.
Also read more about Xintela on the company's website, which you can find here. here.
The text is written by BioStock's editorial team. The content of Biostock's news and analyses is independent, but Biostock's operations are to some extent financed by companies in the industry. This post refers to a company from which BioStock has received funding.
|
Published March 22, 2016
Interview: Xintela's introduction at First North
In connection with the biomedical company Xintela being introduced today at First North in Stockholm, an interview was conducted with the company's CEO Evy Lundgren-Åkerlund, which can be viewed by clicking on the image above or here.
Notes
EMA recommends approval for Gobivaz
GSK CEO Emma Walmsley leaves after eight years
Bactiguard expands clinical evidence in orthopedics
IDL Diagnostics receives patent in Hong Kong
AstraZeneca reports positive Phase III results for Enhertu
NEWSLETTER
NEWS
Sanofi Ventures doubles down on early-stage biotech with $625M boost
Navigating the finansing landscape – insights from BioStock’s expert panel
Genmab acquires Merus for $8 billion
Upcoming events!
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Chronicles
Springtime for biotech – the thaw has begun
Integrum’s fiasco: a stain on a good record
